前列腺癌主动监测中的MRI:我们的实践方法
本文介绍在三级转诊中心约20年常规使用MRI进行前列腺癌主动监测的经验,包括PRECISE评分系统(1-5分评估影像变化:消退、稳定或进展)、肿瘤体积测量方法(单轴或双轴测量、椭球公式或平面测量法)、不同基线风险类别的MRI间隔优化,以及定义有临床意义的进展、重复活检和治疗启动的触发因素。
要点
- PRECISE评分用1-5分传达影像变化:1或2分为消退,3分为稳定,4或5分为进展。
- PRECISE共识组未建立测量肿瘤大小随时间变化的最佳方法,本文讨论单轴或双轴测量及椭球公式或平面测量法估算体积。
- 作者倾向于每次MRI扫描由同一观察者一次性常规测量肿瘤体积。
核心结论
- 系列MRI可增强主动监测的患者选择并允许无创监测肿瘤进展,本文讨论了优化MRI间隔、定义有临床意义的进展及确定重复活检和治疗启动触发因素的方法。
研究设计与样本
- 本文为单中心经验总结,来自三级转诊中心约20年的常规MRI使用实践,非研究论文。
诊断标准与关键数值
- PRECISE评分系统使用1-5分传达影像变化:消退(评分1或2)、稳定(评分3)或进展(评分4或5)。
- PRECISE推荐鼓励在每次随访MRI检查时测量可见病灶,但共识组未建立测量肿瘤大小随时间变化的最佳方法。
临床应用与阅片要点
- 作者倾向每次MRI扫描由同一观察者一次性常规测量肿瘤体积。
- 本文讨论使用单轴或双轴测量或椭球公式或平面测量法估算肿瘤体积。
- 本文讨论如何在不同基线风险类别中优化MRI间隔、定义提示有临床意义进展的大小变化和MRI表现,以及确定重复活检和治疗启动的适当触发因素。
局限性
- PRECISE共识组未建立测量肿瘤大小随时间变化的最佳方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Active surveillance (AS) is an option for deferring or avoiding immediate treatment of low- to intermediate-risk prostate cancer by monitoring the disease to detect progression. Serial MRI enhances patient selection for AS and allows noninvasive monitoring of tumor progression. We have used MRI routinely at entry and during AS in a tertiary referral center for approximately 20 years. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system aims to standardize MRI interpretation and reporting in patients with prostate cancer undergoing AS. It uses a 1-5 scale to convey radiologic change: regression (score of 1 or 2), stability (score of 3), or progression (score of 4 or 5). Although PRECISE recommendations encourage the measurement of visible lesions at each follow-up MRI examination, the consensus group did not establish an optimal way to measure changes in tumor size over time. Methods discussed in this article include using one- or two-axis measurements or estimating tumor volume with the ellipsoid formula or planimetry. We favor the routine measurement of tumor volume on each MRI scan in one sitting by one observer. We also discuss how to optimize intervals for MRI across different baseline risk categories, define the size change and MRI appearance that indicate clinically meaningful progression, and determine appropriate triggers for repeat biopsy and initiation of treatment.
引用
- Giganti F, Allen C, Dickinson L, et al. MRI for Active Surveillance in Prostate Cancer: How I Do It. Radiology. 2026. PMID: 41773966. doi:10.1148/radiol.242164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。